Eli Lilly has partnered with Hims & Hers to sell its obesity drugs, Zepbound and Foundayo, directly to consumers via telehealth. This move intensifies competition with Novo Nordisk, which already utilizes the platform, as both companies vie for market share in the rapidly growing GLP-1 agonist market.
Eli Lilly has announced a partnership with telehealth provider Hims & Hers, enabling direct-to-consumer sales of its obesity drugs, Zepbound and Foundayo. This is a significant strategic move as it directly challenges Novo Nordisk, which has been leveraging the Hims & Hers platform for its Wegovy and Ozempic products since March 2026. The partnership aims to capture a larger share of the booming GLP-1 receptor agonist market by expanding patient access through telehealth. In the short term, this could lead to increased sales for Eli Lilly and Hims & Hers, while potentially putting pressure on Novo Nordisk's market dominance in the direct-to-consumer space. For traders, this represents an opportunity to watch for shifts in market share and sales figures among these key players in the rapidly expanding obesity drug market.